Bringing hope through science
Released
Interim report Q2 2022
EMA's recommendation to approve Pepaxti in EU is foundational for Oncopeptides
CEO Jakob Lindberg
See the Webcast
For further information, please contact:
Rolf Gulliksen
Global Head of Corporate Communications
Q3 report November 9, 2022
rolf.gulliksen@oncopeptides.com
+46 70 262 96 28
Presentation of the Q2 Interim Report 2022
Oncopeptides publishes its report for the second quarter 2022 on August 11, 2022, and will be hosting a webcast on the same day at 14:00 CET. The event will be hosted by CEO, Jakob Lindberg, together with CMO Klaas Bakker and CFO Annika Muskantor. The presentation will be held in English.
Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU
June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.
Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor.
Upcoming events
-
-
Presentation of the Q2 Report 2022 - webcast
14:00 CET
-
-
-
Presentation of the Q1 Report 2022
Oncopeptides published its report for the first quarter 2022 on May 4, 2022, and hosted a webcast on the same day at 11:00 CET. The event was hosted by CEO, Jakob Lindberg and members of the Oncopeptides' Leadership team. The presentation was held in English.
Released
Annual Report 2021
Rolf Gulliksen
Global Head of Corporate Communications
rolf.gulliksen@oncopeptides.com
+46 70 262 96 28
Letter from the CEO - Science is leading the way
"When I look back at 2021, this has been the most revolutionary year in Oncopeptides’ history"
Jakob Lindberg, CEO
Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US
January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US.
Investors, financial analysts and media are invited to participate in a webcast with a Q&A session on January 24, 2022, at 09:00 (CET).
The event will be hosted by CEO, Jakob Lindberg and CMO, Klaas Bakker. The presentation will be held in English.
Jakob interviewed by Di.TV - as new CEO about going forward
In conjunction with the anouncement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.
Jakob Lindberg appointed CEO
On November 15, Oncopeptides announced that the Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO of Oncopeptides. Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020. These changes are effective immediately.
Journey of innovation
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions.
Read more
Vision of Oncopeptides
“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
Cultures & Values
We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.